Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
Learn more: Genome-Wide Analysis Reveals New Strategies to Target Pancreatic Cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Long Island man who survived pancreatic cancer raises funds for PurpleStride walkon April 26, 2024 at 2:55 pm
After 48 years of marriage, three kids, and grandchildren the Stein family's lives were nearly shattered after Howie, a 71-year-old lawyer, was diagnosed with pancreatic cancer.
- PurpleStride Idaho rasises funds to end pancreatic canceron April 26, 2024 at 11:52 am
PurpleStride Idaho, an event raising funds to fight pancreatic cancer, is scheduled for Saturday, April 27 at the Ann Morrison Park Old Timer's Shelter in downtown Boise. Here's what you need to know: ...
- Lisa Niemi Swayze honors her husband's legacy by pushing for more research into pancreatic canceron April 25, 2024 at 5:22 pm
After her husband, Patrick Swayze died of pancreatic cancer, Lisa Niemi Swayze made it her mission to provide awareness and push for more research into one of the world's deadliest forms of cancer.
- Walk to end pancreatic cancer happening all over the countryon April 25, 2024 at 9:21 am
COMMUNITY A WALK TO END PANCREATIC CANCER. TAKING PLACE THIS WEEKEND AT NEARLY 60 VENUES ALL ACROSS THE COUNTRY. AND THAT INCLUDES RIGHT HERE IN SOUTH FLORIDA, JOINING ME TO TALK ABOUT PURPLE STRIDE.
- “Star Trek ”Actress Kitty Swink Had a 4% Survival Rate After Pancreatic Cancer — It's Been 20 Years (Exclusive)on April 25, 2024 at 8:44 am
"Seventeen days later, I came out of Cedars-Sinai with half my stomach, half my pancreas, my gallbladder gone, two feet of my intestines removed out, 28 lymph nodes removed and a 4% chance of ...
- Purple Stride event aims to raise money, awareness for pancreatic canceron April 24, 2024 at 6:52 am
One of the world’s most deadly forms of cancer is the focus of an event in central Iowa this weekend that will gather survivors from across the state, as well as advocates and loved ones of those ...
- Scottsdale pancreatic cancer survivor under the influence of hopeon April 23, 2024 at 12:10 am
The 55-year-old from Scottsdale had to undergo months of radiation, chemotherapy, then surgery. Now, he’s under the influence of hope. It wasn’t his first instinct. “I changed my mind this year,” ...
- Pancreatic Cancer Action Network to hold annual walk on April 27on April 22, 2024 at 6:58 am
Again, the PanCAN Purple Stride Walk for Cincinnati is Saturday, April 27. It’s at East Fork State Park. The event village opens at 8 in the morning. Click here for information.
- What Is Pancreatic Cancer?on April 22, 2024 at 5:30 am
Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably, causing symptoms like fatigue, jaundice, and urinary changes.
- Has Immunotherapy Found Its Place in Pancreatic Cancer?on April 22, 2024 at 4:09 am
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.
via Bing News